CN105801684B - 重组人生长激素及其促进卵泡发育的应用 - Google Patents
重组人生长激素及其促进卵泡发育的应用 Download PDFInfo
- Publication number
- CN105801684B CN105801684B CN201610188088.3A CN201610188088A CN105801684B CN 105801684 B CN105801684 B CN 105801684B CN 201610188088 A CN201610188088 A CN 201610188088A CN 105801684 B CN105801684 B CN 105801684B
- Authority
- CN
- China
- Prior art keywords
- application described
- conjugate
- follicular development
- application
- polyethylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000008217 follicular development Effects 0.000 title claims abstract description 23
- 102000002265 Human Growth Hormone Human genes 0.000 title claims abstract description 7
- 108010000521 Human Growth Hormone Proteins 0.000 title claims abstract description 7
- 239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 7
- 229960004532 somatropin Drugs 0.000 title claims abstract description 7
- 102000018997 Growth Hormone Human genes 0.000 claims abstract description 37
- 108010051696 Growth Hormone Proteins 0.000 claims abstract description 37
- 239000000122 growth hormone Substances 0.000 claims abstract description 37
- 230000035935 pregnancy Effects 0.000 claims abstract description 17
- 239000003814 drug Substances 0.000 claims description 14
- 239000002202 Polyethylene glycol Substances 0.000 claims description 13
- 229920001223 polyethylene glycol Polymers 0.000 claims description 13
- 238000002347 injection Methods 0.000 claims description 9
- 239000007924 injection Substances 0.000 claims description 9
- 230000003068 static effect Effects 0.000 claims description 9
- 125000003277 amino group Chemical group 0.000 claims description 8
- 210000001672 ovary Anatomy 0.000 claims description 6
- 125000005647 linker group Chemical group 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- HOGDNTQCSIKEEV-UHFFFAOYSA-N n'-hydroxybutanediamide Chemical compound NC(=O)CCC(=O)NO HOGDNTQCSIKEEV-UHFFFAOYSA-N 0.000 claims description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- JGMOKGBVKVMRFX-HQZYFCCVSA-N dydrogesterone Chemical compound C1=CC2=CC(=O)CC[C@@]2(C)[C@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 JGMOKGBVKVMRFX-HQZYFCCVSA-N 0.000 claims description 3
- 229960004913 dydrogesterone Drugs 0.000 claims description 3
- 229940011871 estrogen Drugs 0.000 claims description 3
- 239000000262 estrogen Substances 0.000 claims description 3
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 claims description 2
- RSEPBGGWRJCQGY-RBRWEJTLSA-N Estradiol valerate Chemical compound C1CC2=CC(O)=CC=C2[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CCCC)[C@@]1(C)CC2 RSEPBGGWRJCQGY-RBRWEJTLSA-N 0.000 claims description 2
- 208000007984 Female Infertility Diseases 0.000 claims description 2
- 206010021928 Infertility female Diseases 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 claims description 2
- 238000001514 detection method Methods 0.000 claims description 2
- 229960004766 estradiol valerate Drugs 0.000 claims description 2
- 229960002847 prasterone Drugs 0.000 claims description 2
- 238000001542 size-exclusion chromatography Methods 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 abstract description 4
- 230000005923 long-lasting effect Effects 0.000 abstract description 3
- 102000004169 proteins and genes Human genes 0.000 abstract description 3
- 239000013583 drug formulation Substances 0.000 abstract description 2
- 208000000509 infertility Diseases 0.000 description 5
- 230000036512 infertility Effects 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010033165 Ovarian failure Diseases 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 231100000535 infertility Toxicity 0.000 description 3
- 208000021267 infertility disease Diseases 0.000 description 3
- 201000004535 ovarian dysfunction Diseases 0.000 description 3
- 231100000539 ovarian failure Toxicity 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 2
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 206010013883 Dwarfism Diseases 0.000 description 1
- 101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
- 101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940020383 dehydroepiandrosterone 25 mg Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229940060626 estradiol valerate 2 mg Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Endocrinology (AREA)
- Organic Chemistry (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (20)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610188088.3A CN105801684B (zh) | 2016-03-29 | 2016-03-29 | 重组人生长激素及其促进卵泡发育的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610188088.3A CN105801684B (zh) | 2016-03-29 | 2016-03-29 | 重组人生长激素及其促进卵泡发育的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105801684A CN105801684A (zh) | 2016-07-27 |
CN105801684B true CN105801684B (zh) | 2017-04-05 |
Family
ID=56454124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610188088.3A Active CN105801684B (zh) | 2016-03-29 | 2016-03-29 | 重组人生长激素及其促进卵泡发育的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105801684B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108498467B (zh) * | 2018-05-21 | 2019-03-05 | 中山未名海济生物医药有限公司 | 注射用重组人生长激素无菌粉末及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078061A2 (en) * | 2003-03-04 | 2004-09-16 | Aspenbio, Inc. | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
CN101385858A (zh) * | 2008-05-30 | 2009-03-18 | 长春金赛药业有限责任公司 | 纯化的peg化人生长激素缀合物及其药物制剂 |
-
2016
- 2016-03-29 CN CN201610188088.3A patent/CN105801684B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004078061A2 (en) * | 2003-03-04 | 2004-09-16 | Aspenbio, Inc. | Methods and kits for maintaining pregnancy, treating follicular cysts, and synchronizing ovulation using luteinizing hormone |
CN101385858A (zh) * | 2008-05-30 | 2009-03-18 | 长春金赛药业有限责任公司 | 纯化的peg化人生长激素缀合物及其药物制剂 |
Non-Patent Citations (1)
Title |
---|
生长激素对卵巢功能的影响;杨冬,等;《中国妇幼健康研究》;20071231;第18卷(第2期);148-151 * |
Also Published As
Publication number | Publication date |
---|---|
CN105801684A (zh) | 2016-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2010101892A (ru) | Гиалуронидаза и способ ее применения | |
JP2016523248A (ja) | ホルモン分泌調節剤、及びそれを含む組成物 | |
CN101084009A (zh) | Gh促分泌素及其用途 | |
CN107281470A (zh) | 用于受控的卵巢刺激的组合物 | |
US8389479B2 (en) | Compositions and methods for treatment of multiple sclerosis | |
RU2005111253A (ru) | Аналоги ghrh | |
JP4975215B2 (ja) | ゴナドトロピン | |
US20100330093A1 (en) | Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4) | |
JPH05507493A (ja) | 哺乳動物の性腺刺激ホルモンレベルを調節するためのGnRH拮抗薬とGnRHによる組合せ治療 | |
FI116121B (fi) | Menetelmä LHRH-analogin embonaattisuolakoostumuksen valmistamiseksi | |
US20100143485A1 (en) | Oxycontin controlled release formulations and methods of using same | |
CN105801684B (zh) | 重组人生长激素及其促进卵泡发育的应用 | |
US8946161B2 (en) | Method of treatment using stable liquid formulation of G-CSF | |
RU2019109154A (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ ДЛЯ ТЕРАПИИ ДЕФИЦИТА ГОРМОНА РОСТА, СОДЕРЖАЩАЯ СЛИТЫЙ БЕЛОК hGH | |
CA2797658A1 (en) | Casein peptide for use in the treatment of uterine infections | |
RU2018132694A (ru) | Фармацевтическая композиция, включающая рекомбинантный гормон роста человека для лечения дефицита гормона роста | |
JP2023524763A (ja) | コロナウイルス感染症の治療及び予防 | |
KR101095647B1 (ko) | 당단백질 호르몬 조성물 | |
CN107847602A (zh) | 免疫诱导促进组合物和疫苗药物组合物 | |
CN112138148A (zh) | 一种生长激素或其类似物的口服药物组合物 | |
CN109646438A (zh) | 去甲乌药碱或其盐酸盐在制备治疗鼻炎药物中的应用 | |
CA2515297A1 (en) | Use of human chorionic gonadotropin in the treatment of symptoms caused by endometriosis | |
KR101483165B1 (ko) | 인간폐경성선자극호르몬의 조성물 | |
CN105859869B (zh) | 粒细胞巨噬细胞刺激因子及其制剂和应用 | |
CN103520706A (zh) | 口服用重组人血清白蛋白融合蛋白制剂配方、产品及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CP03 | Change of name, title or address |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Changchun Genscience Pharmaceuticals Co., Ltd. Address before: 130012 Jilin province Changchun high tech Zone more Road No. 1718 Patentee before: Jinsai Drug Co., Ltd., Changchun |
|
CP03 | Change of name, title or address | ||
CP01 | Change in the name or title of a patent holder |
Address after: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee after: Jinsai Drug Co., Ltd., Changchun Address before: 130012 No. 72 Tianhe street, hi tech Industrial Development Zone, Jilin, Changchun Patentee before: Changchun Genscience Pharmaceuticals Co., Ltd. |
|
CP01 | Change in the name or title of a patent holder |